RYTM News and Press, Rhythm Pharmaceuticals Inc. From 04/08/22

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that on April 4, 2022, the Compensation Committee o...

Gainers: Advent Technologies (ADN) +79%. Tufin Software Technologies (TUFN) +43%. Mobiquity Technologies (OTCQB:MOBQ) +30%. Missfresh (MF) +25%. Venator Materials (VNTR) +17%. Team (TISI) +16%. Concord Medical Services (CCM) +15%. NextDecade (NEXT) +15%. Smart Sand (SND) +13%. ...

– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled in EMANATE – – Ongoing Phase 2 DAYBREAK trial to focus initially on 10 genes with strongest relev...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Start Time: 08:00 End Time: 09:02 Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2021 Earnings Conference Call March 01, 2022, 08:00 AM ET Company Participants David Meeker - Chairman, President and CEO Linda Shapiro - CMO Hunter Smith - CFO Yann Mazabraud - EVP, Head of International Jennifer Chien ...

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Off...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals press release (NASDAQ:RYTM): Q4 GAAP EPS of -$0.85 beats by $0.06. Revenue of $1.82M beats by $0.12M. For further details see: Rhythm Pharmaceuticals GAAP EPS of -$0.85 beats by $0.06, revenue of $1.82M beats by $0.12M

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setm...